This document discusses body fluid composition, movement, regulation, and disturbances of sodium, potassium, calcium, and acid-base balance. It provides details on:
- The composition of extracellular fluid (ECF) and intracellular fluid (ICF) and gastrointestinal secretions.
- How fluid moves between compartments based on Starling forces and osmolality.
- Sodium, potassium, and calcium metabolism, including intake, excretion, regulation, and causes and treatment of hypo- and hyper- conditions.
- Signs and symptoms and treatment approaches for disturbances in these electrolytes.
general presentation and management of Fluid & Electrolyte.pptxNatnael21
Discussion about physiology of fluid balance in human and clinical presentation and general management principles of major electrolyte abnormality like hypernatremia hyponatremia hyperkalemia and hypokalemia
general presentation and management of Fluid & Electrolyte.pptxNatnael21
Discussion about physiology of fluid balance in human and clinical presentation and general management principles of major electrolyte abnormality like hypernatremia hyponatremia hyperkalemia and hypokalemia
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
4. BODY FLUID COMPOSITION
• ECF- composition of plasma and interstitial
fluids differs only slightly
- principal cation- Na+
- principal anion- Cl-, HCO3
-
• ICF- principal cations- K+, Mg+2
- principal anions- organic phosphate esters
(ATP, creatinine phosphate, phospholipids) and
proteins
2/16/2023 4
6. Composition of GI Secretions
Type of
Secretion
Volume
(mL/24 h)
Na (mEq/L) K (mEq/L) Cl (mEq/L) HCO3
–
(mEq/L)
Stomach 1000–2000 60–90 10–30 100–130 0
Small
intestine
2000–3000 120–140 5–10 90–120 30–40
Colon — 60 30 40 0
Pancreas 600–800 135–145 5–10 70–90 95–115
Bile 300–800 135–145 5–10 90–110 30–40
2/16/2023 6
7. FLUID MOVEMENT
• Fluid movement between plasma and
interstitial space depends on Starling forces
(hydraulic and colloid osmotic or oncotic
pressure)
• Fluid movement between ECF and ICF
depends on osmolality. An isotonic change in
volume in either one of the compartments is
not accompanied by the net movement of
water
2/16/2023 7
8. FLUID MOVEMENT ctd
- Total osmolality= effective + ineffective osmolality
- Effective osmolality- determined by solutes
restricted to their compartment.
- is equivalent to tonicity
- ECF - Na+, glucose, mannitol, glycine
- ICF - K+, amino acids, organic acids
- Ineffective osmoles- move freely between
compartments and don’t affect the water shift
- urea, ethanol, and methanol
2/16/2023 8
10. CLASSIFICATION OF BODY FLUID CHANGES
• Volume
• Concentration
• Composition
2/16/2023 10
11. Sodium Balance
• Total body sodium ~ 5000 mmol, of which 44% is in
the extracellular fluid, 9% in the intracellular fluid
and the remaining 47% in bone
• Normal plasma level= 135-145 mEq/L
• Intake
- Average consumption/day= 3-5 g of NaCl (130
to 217 mmol Na+)/day
- Results in ECF expansion and renal excretion
• Excretion
- Renal tubule reabsorption is the major
regulatory mechanism (not GFR)
2/16/2023 11
12. Tubular reabsorption
- 2/3 in proximal
convoluted tubule
- 25-30% in thick
ascending limb of
loop of Henle
- 5% in distal
convoluted tubule
- The rest in cortical
and medullary
collecting ducts
2/16/2023 12
13. Sodium Balance CTD…
• The output of sodium via urine and sweat is under the
control of the adrenal corticoids, the most powerful
conservator of sodium being aldosterone.
The sodium excretion shut down of trauma
• Following trauma/surgery there is a variable period of
reduced excretion of sodium (up to 48 hrs) due to increased
adrenocortical activity.
2/16/2023 13
14. HYPONATREMIA
- The commonest electrolyte abnormality in hospitalized
patients (up to 20%)
- A plasma Na+ concentration less than 135 mmol/L
- Cause:
A) Inadequate intake- reduced dietary or IV
replacement
B) loss of fluid containing sodium – sweat, GIT
(vomiting, diarrhea, fistula, ileus, obstruction),
urine (diuretics, recovery from ARF, lack of
aldosterone)
2/16/2023 14
15. Symptoms and signs
Body System Hyponatremia
Central nervous system Headache, confusion, hyperactive or
hypoactive deep tendon reflexes, seizures,
coma, increased intracranial pressure
Musculoskeletal Weakness, fatigue, muscle cramps/twitching
GI Anorexia, nausea, vomiting, watery diarrhea
Cardiovascular Hypertension and bradycardia if significant
increases in intracranial pressure
Tissue Lacrimation, salivation
Renal Oliguria
2/16/2023 15
16. Management
- Ix : Plasma osmolality will decrease
: Urine osmolality <100mosm/kg and SG <1.003
: Urine Na+ concentration < 20 mmol/l (less)
- Rx: Mild– no Rx
: Moderate (symptomatic)- water restriction, restore
blood volume with isotonic saline.
: Severe (neurological manifestation) – treat with
hypertonic saline with an aim of
correcting 0.5-1mmol/l per hr and a
maximum of 10-12mmol/L/day.
2/16/2023 16
17. HYPERNATREMIA
- Plasma Na+ concentration greater than 145 mmol/L.
- Cause:
A) Loss of water – the physically handicapped,
patients with impaired mental status, in the postop
state, and in intubated patients in the ICU
- renal loss due to drug induced (diuretics),
osmotic diuresis (DM, mannitol, endogenous urea
from high protein diet etc)
B) Excessive gain – excessive N/S given during post op
time
2/16/2023 17
18. Signs and symptoms
Body System Hypernatremia
Central nervous system Restlessness, lethargy, ataxia,
irritability, tonic spasms, delirium,
seizures, coma
Musculoskeletal Weakness
Cardiovascular Tachycardia, hypotension, syncope
Tissue Dry sticky mucous membranes, red
swollen tongue, decreased saliva
and tears
Renal Oliguria
Metabolic Fever
2/16/2023 18
19. Treatment
• The aim is to replace the water deficit and treat
the underlying condition
• Water deficit can be calculated as:
Water deficit(L)= (serum Na-140 )X TBW
140
• Corrected slowly over 48-72 hrs
• Rate of correction- no more than 0.5mmol/L/hr or
12 mmol/L/24 hr
• Aim for a decrease in serum sodium of 1 mEq/L/h
(1 mmol/L/h)
• Safest route is po but if it is not possible 5%D/W
or 0.45%NaCl
2/16/2023 19
20. Potassium Balance
• Serum levels are 3.5-5.0 mEq/L
• More than 98% of the potassium is found in the ICF
• Intake- Daily intake ~ 50-100 mEq/day
• Loss- pushed into cells by insulin and
cathecholamines Na-K ATPase
- excreted in urine
- GI loss- 10% (can increase to 50-60%)
- also affected by serum pH
2/16/2023 20
21. Tubular reabsorption
- 90% in proximal
convoluted tubule and
thick ascending limb of
loop of Henle.
- The rest in distal
convoluted tubule and
cortical collecting duct
- Regulated by aldosterone,
hyperkalemia and urine
flow rate
2/16/2023 21
22. HYPOKALEMIA
- Plasma K+ concentration <3.5 mmol/L
Cause :
A) Inadequate nutritional intake/ inadequate potassium
replacement Rx
B) Increased loss – renal (diuretics, steroid,
hyperaldestorinism, ↓tubular K+ re-absorption), GIT
(intestinal ileus, vomiting, ileostomy, fistula,
diarrhea, villous adenoma of colon)
C) K+ shift from ECF to ICF – insulin, alkalosis
2/16/2023 22
23. Signs and symptoms
System Potassium
GI Ileus, constipation
Neuromuscular Decreased reflexes, fatigue,
weakness, paralysis
Cardiovascular Arrest
ECG- inverted T wave, depressed ST
segment, prolonged PR
2/16/2023 23
24. Treatment
• Correct the deficit and minimize ongoing loss
• Safer to correct it po
• Dextrose containing fluids worsen
hypokalemia.
• KCl- corrects both hypokalemia and alkalosis
• KHCO3 and citrate- in diarrhea or renal tubular
acidosis
• 600 mg KCl tablet = 8 mmol of K+
2/16/2023 24
25. Treatment CTD…
- Asymptomatic, tolerating enteral nutrition:
- KCl 40 mEq per enteral access x 1 dose
- Asymptomatic, not tolerating enteral nutrition:
- KCl 20 mEq IV q2h x 2 doses
- Symptomatic: KCl 20 mEq IV q1h x 4 doses
- Recheck potassium level 2 h after end of infusion
- The rate of administration should not exceed 20 mEq
/hour.
- Hypomagnesemia frequently accompanies
hypokalemia and generally must be corrected to
successfully replenish K+.
2/16/2023 25
26. HYPERKALEMIA
Plasma potassium conc.>5.0mmol/l
Cause:
A) Increase intake - oral, parenteral (massive blood
transfusion, Iv potassium)
B) Reduced excretion – Renal failure, acidosis, drugs
(potassium sparing diuretics, ACE-inhibitors,
NSAID, β-blockers)
C) Shift from ICF to ECF –insulin deficiency,
acidosis, tissue injury (burn, surgery, poly trauma),
haemolysis
2/16/2023 26
27. Signs and symptoms
System Potassium
GI Nausea/vomiting, colic, diarrhea
Neuromuscular Weakness, paralysis, respiratory
failure
Cardiovascular Arrhythmia, arrest
ECG- peaked T waves, prolonged
PR intervals
2/16/2023 27
28. Treatment
• Goals:
- To minimize membrane depolarization
- Shift K + into cells
- Promote K + loss
- Decrease exogenous intake and antikalliuretic
drugs
- Protect cells from effects of increased K +
2/16/2023 28
29. Treatment CTD…
1) Mild hyperkalemia (K+ = 5 to 6 mmol/L)
- Conservative treatment :
- reduction of daily K+ intake
- loop diuretic (e.g., furosemide)
- discontinue any medication that is capable of
impairing K+ homeostasis (e.g., β-adrenergic
antagonists, ACE inhibitors, K+-sparing
diuretics, NSAIDs)
2/16/2023 29
30. Treatment CTD…
2) Severe hyperkalemia (K+ >6.5 mmol/L)
• Temporizing measures
– 10% Calcium gluconate (5 to 10 mL intravenously over
2 minutes) to stabilize the myocardium.
– Dextrose (0.5 g/kg body weight) with insulin (0.3 unit of
regular insulin/g of dextrose). The usual dose is 25 g
dextrose + 6-10 units of regular insulin iv bolus
– NaHCO3 [1 mmol/kg or 1 to 2 ampoules (50 mL each) of
8.4% NaHCO3] can be infused iv over a 3- to 5-minute
period. This dose can be repeated after 10 to 15 minutes
if ECG abnormalities persist.
– Inhaled β-agonists- e.g., albuterol sulfate, 2 to 4 mL of
0.5% solution (10 to 20 mg) delivered via nebulizer
2/16/2023 30
31. Treatment CTD…
• Therapeutic measures
– Sodium polystyrene sulfonate (Kayexalate):
- 20 to 50 g in 100 to 200 mL of 20%
sorbitol po every 4 hours
- 50 g of the resin as a retention enema
in 50 mL of 70% sorbitol added to 100
to 200 mL of water every 1 to 2 hours,
followed by administration every 6 hrs
– Hydration with 0.9% NaCl + loop diuretic +
thiazide diuretic
– Dialysis
2/16/2023 31
32. Calcium Metabolism
• Total body calcium ~ 1-2 kg
• 99% is in the skeleton
• Serum Ca level- 8.5 to 10.5 mEq/L of which 50%
(4.2 to 4.8 mg/dL) is ionized, 40% is bound to
proteins and 10% is complexed to phosphate
and other anions
• Alterations in serum protein affects total blood Ca
while acidosis affects the ionized part
• Controlled by PTH and 1,25(OH)2 D
2/16/2023 32
33. Calcium Metabolism CTD…
• Intake
- 10-37 mmol (400-1500mg/d)
- intestinal absorption actively and passively controlled
by 1,25(OH)2D
- require gastric acid, blunted in pancreatic or biliary
insufficiency
• Loss
- 100-200mg/d through the intestine
- kidneys - regulated by ionized Ca+2
- reabsorption- 65% in PCT, 20% in
TALH, ~10% in DCT
- PTH stimulates absorption from intestine and kidney
• If homeostatic mechanism fails PTH and Vit D activate
osteoclastic bone resorption
2/16/2023 33
34. HYPOCALCEMIA
• serum calcium level <8.5 mEq/L or ionized
calcium level <4.2 mg/dL
• Cause: After thyroid/parathyroid surgery,
hypoproteinemia, acute pancreatitis, Vit-D
deficiency, magnesium deficiency, alkalosis
• The most common cause of low total serum
calcium is hypoalbuminemia
2/16/2023 34
36. Treatment
• Severe, Symptomatic Hypocalcemia
- 10% Ca gluconate (10–20 mL) iv over 10–15
minutes
- followed by 10-15 mg/kg of calcium (6-8 10-
mL vials of 10% calcium gluconate) added to 1
L of D5W and infused over 4–6 hours.
- monitor serum levels frequently
• Asymptomatic Hypocalcemia
- Ca supplements (1000-1500 mg/d elemental
Ca) in divided doses
- Vit D2 or D3 25,000-100,000 IU/day
- Calcitriol 0.25-2 μg/d
2/16/2023 36
37. Hypercalcemia
• Serum Ca + 2> 10.5 mEq/L
• Most common causes are primary
hyperparathyroidism and malignancy-associated
hypercalcemia.
• Hypercalciuria usually precedes hypercalcemia.
• Most often, asymptomatic, mild hypercalcemia (11
mg/dL) is due to primary hyperparathyroidism,
whereas the symptomatic, severe hypercalcemia (14
mg/dL) is due to hypercalcemia of malignancy
2/16/2023 37
38. Signs and symptoms
• Mild hypercalcemia (up to 11-11.5 mg/dl)
- asymptomatic
- vague neuropsychiatric symptoms
- PUD, nephrolithiasis
• More severe (>12-13 mg/dl)
- lethargy, stupor, coma
- nausea, anorexia, constipation, pancreatitis
- polyuria, polydipsia
- bone pain, pathologic fracture
2/16/2023 38
39. Treatment
• Mild, asymptomatic- no immediate therapy
• Symptomatic
- Volume expansion- 4-6 L of N/S iv over 24 hrs
followed by loop diuretics
- Bisphosphonates- in malignancy related
- Zoledronic acid 4 mg iv over 30 min
- Pamidronate 60-90 mg iv over 2-4 hrs
- Etidronate 7.5 mg/kg/day for 3-7 dys
- Glucocorticoids- for Vit D related
- Hydrocortisone 100-300 mg iv/day
- Prednisone 40-60 mg po/day for 3-7 dys
2/16/2023 39
40. ACID-BASE BALANCE
• The pH is maintained in a narrow range (7.35-
7.45)
• Acid-base homeostasis represents equilibrium
among concentration of H+, PCO2, and HCO3
-
• The endogenous acid load is efficiently neutralized
by buffer systems and ultimately excreted by lungs
and kidneys
• Important buffers:
- ICF- proteins and phosphates
- ECF- bicarbonate-carbonic acid system
• Compensations can be by respiratory or metabolic
mechanisms
2/16/2023 40
41. ACID-BASE imBALANCE
• Arterial blood pH normally 7.4
– Acidosis – pH below 7.35
– Alkalosis – pH above 7.45
• Respiratory acidosis and alkalosis
– Disorders resulting from changes in partial pressure of CO2
in arterial blood
• Metabolic acidosis and alkalosis
– Disorders resulting from changes in HCO3
- concentration in
arterial blood
2/16/2023 41
42. Functional anatomy and physiology
of acid–base homeostasis
• A variety of physiological mechanisms maintain the
pH of the ECF. The first is the action of blood and
tissue buffers, of which the most important involves
reaction of H+ ions with bicarbonate to form carbonic
acid, which, under the influence of the enzyme
carbonic anhydrase (c.a.), dissociates to form CO2
and water
2/16/2023 42
43. • Respiratory compensation for acid–base
disturbancescan occur quickly. In response to acid
accumulation, pH changes in the brain stem stimulate
ventilatory drive, serving to reduce the PCO2 and
hence drive up the pH .
• Conversely, systemic alkalosis leads to inhibition of
ventilation (although this is limited because hypoxia
provides an alternative stimulus to ventilation).
2/16/2023 43
44. • The kidney provides a third line of defence against
disturbances of arterial pH. When acid accumulates
due to chronic respiratory or metabolic (non-renal)
causes, the kidney has the long-term capacity to
enhance urinary excretion of acid, effectively
increasing the plasma bicarbonate.
2/16/2023 44
45. • Distal nephron segments have an important role in
determining net acid excretion by the kidney. In the
intercalated cells of the cortical collecting duct and
the outer medullary collecting duct cells, acid is
secreted into the lumen by an H+-ATPase.
• The secreted H+ ions contribute to the reabsorption of
any residual bicarbonate present in the luminal fluid,
but also contribute net acid for removal from the
body, bound to a variety of urinary buffers
2/16/2023 45
46. Metabolic acidosis
Aetiology and assessment
• Metabolic acidosis occurs when an acid other
than carbonic acid (due to CO2 retention)
accumulates in the body, resulting in a fall in
the plasma bicarbonate.
2/16/2023 46
47. • If the kidneys are intact (i.e. not the cause of
the initial disturbance), renal excretion of acid
can be gradually increased over days to weeks,
raising the plasma bicarbonate and hence the
pH towards normal in the new steady state.
2/16/2023 47
49. Metabolic alkalosis
Aetiology and clinical assessment
• Metabolic alkalosis is characterised by an increase in
the plasma bicarbonate concentration and the plasma
pH.
• There is a compensatory rise in PCO2 due to
hypoventilation, but this is limited by the need to
avoid hypoxia.
2/16/2023 49
50. • The causes are best classified by the
accompanying disturbance of ECF volume.
A. Hypovolaemic metabolic alkalosis
is the most common pattern, typified by
disorders such as sustained vomiting in which
acid-rich fluid is lost directly from the body.
2/16/2023 50
51. B. Normovolaemic (or hypervolaemic) metabolic
alkalosis
• occurs when both bicarbonate retention and
volume expansion occur simultaneously.
• Classical causes include corticosteroid excess
states such as primary
hyperaldosteronism,Cushing’s syndrome and
corticosteroid therapy.
• Occasionally, overuse of antacid salts for
treatment of dyspepsia produces a similar pattern.
2/16/2023 51
52. Respiratory acidosis
• Respiratory acidosis occurs when there is
accumulation of CO2 due to reduced effective
alveolar ventilation .
• This results in a rise in thePCO2, with a
compensatory increase in plasma bicarbonate
concentration
2/16/2023 52
53. Respiratory alkalosis
• Respiratory alkalosis develops when there is a period
of sustained hyperventilation resulting in a reduction
of PCO2 and increase in plasma pH.
• If the condition is sustained,renal compensation
occurs such that tubular acid secretion is reduced and
the plasma bicarbonate falls.
2/16/2023 53
54. Treatment
A) Acidosis
- Alkali …reserved for - severe acidemia
- Severe acidosis, pH <7.2
- Monitoring of electrolytes
- Goal of Rx: pH >7.35,Bicarbonate >10mEq/L
- Correction of underlying condition
B) Alkalosis
- Correct underlying stimulus for bicarbonate
generation
- Remove factors that sustain bicarbonate re-
absorption
- Acidification by oral NH4Cl
- Hemodialysis
2/16/2023 54